ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. ProPublica on Friday published never-before-released data ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Albertans may see more and less-expensive varieties of Ozempic on the market soon, after a patent on the drug expired two weeks ago. Ozempic has made headlines in recent years as a popular weight-loss ...

The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...

Walking past the Makera booth at CES 2026, the first thing you notice isn't the smell of sawdust or the high-pitched whine of a typical workshop. Instead, it's a row of sleek, enclosed machines that ...

On January 8, 2026, Collegium Pharmaceutical, Inc. issued full-year 2026 guidance, projecting US$805 million to US$825 million in net product revenues and highlighting new authorized generic supply ...

Granules Pharmaceuticals, a wholly-owned subsidiary of Granules India, has received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for ...

THIRUVANANTHAPURAM: When it comes to medicines, a higher price tag doesn’t mean better quality. In what could go a long way in cutting down medicine expenses—in some cases up to Rs 66,000 a year—a ...

Drug companies in Canada are allowed to make lower priced generic versions of the blockbuster drug Ozempic as of next week, but experts say patients shouldn’t expect it to be available for at least a ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

Federal Judge Denies Big Pharma's Motion to Shut Down Multistate Dermatological Generic Drug Price Fixing Lawsuit "A reasonable juror could find that the defendants’ 'blaming supply,' making ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...